Real-World Toxicity and Hospitalization Outcomes Following Immunotherapy for Malignant Pleural Mesothelioma
Introduction Malignant pleural mesothelioma (MPM) is an aggressive disease with poor outcomes despite advances in systemic treatment. Combination immune checkpoint inhibitor therapy with nivolumab and ipilimumab is increasingly used in clinical practice for advanced MPM; however, real-world treatment outcomes and treatment-related toxicities remain important considerations. This study evaluated survival outcomes, treatment response, toxicity, and hospitalization in patients with advanced mesothelioma receiving combination immunotherapy with nivolumab and ipilimumab. Methods We conducted a retrospective cohort study of 24 patients with advanced mesothelioma who received nivolumab and ipilimumab at a tertiary NHS hospital in Birmingham, United Kingdom, between April 2021 and October 2025. Demographic and clinical characteristics, treatment exposure, radiological response, progression-free survival (PFS), overall survival (OS), adverse events, and hospital admissions were reviewed. Survival outcomes were assessed using Kaplan-Meier analysis. Results Twenty-four patients were included, of whom 23 (95.8%) had pleural disease and 14 (58.3%) had an Eastern Cooperative Oncology Group performance status of 1. The median number of treatment cycles was five (range, 1-24). Recorded response categories were progressive disease in 12 patients (50%), stable disease in seven (29.2%), partial response in three (12.5%), and mixed response in two (8.3%). Median PFS was 4.5 months, and median OS was 9.5 months. Grade 3 or higher immune-related adverse events occurred in six patients (25%). Twenty patients (83.3%) experienced at least one hospital admission, with 36 admission episodes recorded. Admissions were attributed to immunotherapy-related adverse effects in 16 patients and disease-related or other non-immune complications in four patients. Conclusions Outcomes following nivolumab and ipilimumab varied considerably in this real-world cohort. Hospital admissions occurred in a substantial proportion of patients and were attributed to both immunotherapy-related adverse effects and disease-related complications. These findings highlight the importance of careful assessment, toxicity recognition, and multidisciplinary management during treatment.
Authors
- Reshma David
- Rehmatullah Khan
Institutions
- University Hospitals Birmingham NHS Foundation Trust (GB)
- Queen Elizabeth Hospital Birmingham (GB)
Publication Details
- Journal
- Cureus
- Published
- 2026-11-14
- DOI
- https://doi.org/10.7759/cureus.119661
- Primary Topic
- Occupational and environmental lung diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00